mRNA-4106
Phase 1Active 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Mar 25, 2025 → Jan 10, 2029
NCT ID
NCT06880549About mRNA-4106
mRNA-4106 is a phase 1 stage product being developed by Moderna for Advanced Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT06880549. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06880549 | Phase 1 | Active |
Competing Products
20 competing products in Advanced Solid Tumors